ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1688 • ACR Convergence 2021

    Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 9.3 Years: An Updated Integrated Safety Analysis

    Peter C Taylor1, Tsutomu Takeuchi2, Gerd Burmester3, Patrick DUREZ4, Josef Smolen5, Walter Deberdt6, Jinglin Zhong7, Jorge Ross Terres6, Natalia Bello6 and Kevin Winthrop8, 1University of Oxford, Oxford, United Kingdom, 2Div. Rheumatology, Keio University, Tokyo, Japan, 3Charité University Medicine Berlin, Berlin, Germany, 4Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium, 5Medical University of Vienna, Vienna, Austria, 6Eli Lilly and Company, Indianapolis, IN, 7IQVIA, Morrisville, NC, 8Oregon Health & Science University, Portland, OR

    Background/Purpose: Baricitinib (bari) is an oral selective Janus kinase (JAK)1/JAK 2 inhibitor approved for the treatment of adult patients with moderately to severely active rheumatoid…
  • Abstract Number: 1651 • ACR Convergence 2021

    Symptom Trajectories in the Transition from Pre-Rheumatoid Arthritis to Clinically-Apparent Inflammatory Arthritis

    Salina Haville1, Jennifer Seifert1, Saman Barzideh1, LauraKay Moss1, Navin Rao2, Alyssa Johnsen3, Jane Buckner4, Eddie James5, Sylvia Posso4, Gary Firestein6, David Boyle7, William Robinson8, V. Michael Holers9 and Kevin Deane10, 1University of Colorado Denver, Aurora, CO, 2Janssen R&D, Spring House, PA, 3Janssen R&D, Princeton Junction, NJ, 4Benaroya Research Institute at Virginia Mason, Seattle, WA, 5Benaroya Research Institute at Virginia Mason, Monroe, WA, 6University of California San Diego, San Diego, CA, 7University of California San Diego, La Jolla, CA, 8Stanford University, Palo Alto, CA, 9University of Colorado, Denver, CO, 10University of Colorado Denver, Denver, CO

    Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period definable as elevations of antibodies to citrullinated protein antibodies (ACPA) before clinically-apparent inflammatory arthritis (IA). ACPA elevations…
  • Abstract Number: 1673 • ACR Convergence 2021

    Riding Multiple Waves of Uncertainty: Real World Canadian RA Patient Outcomes over 1 Year of COVID-19 Restrictions

    Orit Schieir1, Susan Bartlett2, Marie-France Valois2, Louis Bessette3, Gilles Boire4, Glen Hazlewood5, Carol Hitchon6, Edward Keystone7, Janet Pope8, Diane Tin9, Carter Thorne10, Vivian Bykerk11 and CATCH Investigators12, 1Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, 2McGill University, Montréal, QC, Canada, 3Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 4Universite de Sherbrooke, Sherbrooke, QC, Canada, 5University of Calgary, Calgary, AB, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 8University of Western Ontario, London, ON, Canada, 9The Arthritis Program Research Group, Newmarket, ON, Canada, 10Southlake Regional Health Centre, Newmarket, ON, Canada, 11Hospital for Special Surgery, New York, NY, 12Mt Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: During the COVID-19 pandemic, Canadians adults with RA faced considerable uncertainty due to greater risk of infection, hospitalization, changing access to RA medications, and…
  • Abstract Number: 1704 • ACR Convergence 2021

    Tofacitinib in Rheumatoid Arthritis: Is There a Correlation Between a Rapid Analgesic Effect and a Decrease in Activity After 3 and 6 Months?

    Elena Pogozheva1, Andrey Karateev1, Evgeniy Nasonov1, Alexander Lila1, Vadim Mazurov2, Rusanna Samigullina3, Diana Chakieva4, Anna Dadalova4, Anna Dyo4, Andrey Baranov5, Natalia Lapkina5, Ekaterina Kol’tsova6, Ivan Shchendrigin7, Tatyana Rasevich8, Antonina Davydova9, Irina Shafieva10, Inna Bashkova11, Daria Bobrikova12, Irina Kushnir13, Elena Kalinina14, Tatiana Sal’nikova15, Valentina Sorotskaya16, Irina Marusenko17, Olga Semagina18, Irina Vinogradova19, Diana Krechikova20, Natalia Kiryukhina21, Irina Semizarova22, Dzhamilya Murtazalieva23 and Marina Semchenkova24, 1V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia, 2Mechnikov North-Western State Medical University, Saint Petersburg, Russia, 3Mechnikov North-Western State Medical University, St.Petersburg, Russia, 4Mechnikov North-Western State Medical University, St. Petersburg, Russia, 5Yaroslavl State Medical University, Yaroslavl, Russia, 6Scientific and Research Institute of Health Care Organization, Moscow, Russia, 7Stavropol Regional Clinical Hospital, Stavropol, Russia, 8Astrakhan Region Alexandro-Mariinsky Regional Clinical Hospital, Astrakhan, Russia, 9Regional Clinical Hospital №1 named. prof. S. V. Ochapovskogo, Krasnodar, Russia, 10Samara State Medical University of the Ministry of Health of the Russian Federation, Samara, Russia, 11Advisory Polyclinic Chuvash State University named after I. N. Ulyanov, Cheboksary, Russia, 12Regional Clinical Hospital No. 1, Tyumen', Russia, 13Kemerovo regional clinical hospital, Kemerovo, Russia, 14Volgograd State Medical University, Volgograd, Russia, 15Regional Clinical Hospital, Tula, Russia, 16Tula State Medical University, Tula, Russia, 17Petrozavodsk State University, Petrozavodsk, Russia, 18Regional Clinical Hospital, Samara, Russia, 19Regional Clinical Hospital, Ulyanovsk, Russia, 20Smolensk State Medical University, Smolensk, Russia, 21National Medical and Surgical Center named after N.I. Pirogov” of the Ministry of Healthcare of the Russian Federation, Moscow, Russia, 22Regional Clinical Hospital, Krasnodar, Russia, 23Moscow Clinical Scientific and Practical Centre named after Loginov A.S., Moscow, Russia, 24Medical Clinical Centre, Smolensk, Russia

    Background/Purpose: to investigate the correlation between the rapid analgesic effect of tofacitinib and a decrease in RA activity after 3 and 6 months.Methods: The study…
  • Abstract Number: 1683 • ACR Convergence 2021

    Abatacept in Usual and in Non-Specific Interstitial Pneumonia Associated to Rheumatoid Arthritis. National Multicenter Study of 190 Patients

    Belén Atienza-Mateo1, Carlos Fernández-Díaz2, Santos Castañeda3, Rafael Melero4, Francisco Ortiz-Sanjuán5, Ivette Casafont6, Sebastián C. Rodríguez-García7, Iván Ferraz-Amaro8, Miguel Ángel gonzalez-Gay9 and Ricardo Blanco10, 1Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Reina Sofía, Murcia, Spain, 3Hospital Universitario de la Princesa, Madrid, Spain, 4Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, 5Hospital Universitario La Fe, Valencia, Spain, 6Hospital Universitari Germans Trias i Pujol, Barcelona, Badalona, Spain, 7Hospital Universitario Clinic, Barcelona, Spain, 8Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 9Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 10Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a severe complication of Rheumatoid Arthritis (RA). Usual interstitial pneumonia (UIP) is considered to be more frequent and severe…
  • Abstract Number: 1699 • ACR Convergence 2021

    The “ITIS” Diet Improves Fatigue in Patients with Rheumatoid Arthritis and Is Associated with Changes in Metabolome and Fecal Microbiome

    Roxana Coras1, Cameron Martino1, Julia Gauglitz1, Alan Jarmusch1, Anupriya Tripathi1, Francesca Cedola2, Marta Fernandez-Bustamante1, Meritxall Agustín-Perez1, Maram Alharthi1, Susan Lee1, Abha Singh1, Soo In Choi1, Tania Rivera1, Katherine Nguyen3, Tatyana Shekhtman1, Tiffany Holt1, Shahrokh Golshan1, Rob Knight1, Pieter C Dorrestein1 and Monica Guma1, 1University of California San Diego, La Jolla, CA, 2University of California San Diego, Rome, CA, Italy, 3University of California San Diego, San Diego, CA

    Background/Purpose: Fatigue is common symptom in rheumatoid arthritis (RA), associated with decreased quality of life and productivity. Fatigue mechanisms have not been well studied, hence,…
  • Abstract Number: 1712 • ACR Convergence 2021

    Adverse Outcomes and Rehospitalization After Delivery Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis and Their Infants

    Julianna Sabo1, Namrata Singh2, Deborah Crane1, David Doody3, Melissa Schiff4 and Beth Mueller5, 1University of Washington, Seattle, WA, 2University of Washington, Bellevue, WA, 3Fred Hutchinson Cancer Research Center, Seattle, WA, 4University of Washington, University of New Mexico, Seattle, WA, 5Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA

    Background/Purpose: Women with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) have greater risk of adverse obstetric and birth outcomes than women without these conditions.…
  • Abstract Number: 1703 • ACR Convergence 2021

    AP1189: A Novel Oral Biased Melanocortin Agonist with Anti-inflammatory and Pro-resolving Effect for the Treatment of Rheumatoid Arthritis

    Thomas Jonassen1, Thierry Duvauchelle1, Birgitte Telmer2, Irene Sandholdt2, Thomas Boesen1 and Ellen-Margrethe Hauge3, 1SynAct Pharma, Holte, Denmark, 2CroxxMed, Hørsholm, Denmark, 3Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: Melanocortin (MC) type 1 and type 3 receptor stimulation is associated with anti-inflammation and promotion of inflammatory resolution. AP1189 is a biased MC type…
  • Abstract Number: 1695 • ACR Convergence 2021

    Erythrocyte Methotrexate Polyglutamates Are Substantially Higher After Subcutaneous Methotrexate Treatment in Rheumatoid Arthritis Patients in the First Months of Treatment

    Renske Hebing1, Sohaila Mahmoud1, Marry Lin2, Ittai Muller2, Sandra Heil3, Willem Lems4, Mike Nurmohamed5, Robert de Jonge2 and Gerrit Jansen2, 1Reade, Amsterdam, Netherlands, 2AmsterdamUMC, Amsterdam, Netherlands, 3ErasmusMC, Rotterdam, Netherlands, 4VUmc, Amsterdam, Netherlands, 5Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands

    Background/Purpose: Optimal dosing of methotrexate (MTX) for individual rheumatoid arthritis (RA) patients to achieve adequate disease control remains challenging. Assessment of erythrocyte MTX-polyglutamates (PGs) levels…
  • Abstract Number: 1650 • ACR Convergence 2021

    Identifying Trajectories and Endotypes in the Evolution of Pre-Rheumatoid Arthritis with Autoantibody Testing and Artificial Adaptive System Analysis

    Paolo Massimo Buscema1, Giulia Massini2, Francesca Della Torre2, Masoud Asadi-Zeydabadi3, Colin O'Donnell4, Francis Newman5, Randall Tagg3, Weldon Lodwick5, Christopher Collora4, Marie Feser4, LauraKay Moss4, William Robinson6, Geoffrey Thiele7, Ted Mikuls7, Jess Edison8, V. Michael Holers4 and Kevin Deane9, 1Semeion Research Center of Sciences of Communication; University of Colorado Denver Department of Mathematical and Statistical Sciences, Rome, Italy, 2Semeion Research Center of Sciences of Communication, Rome, Italy, 3University of Colorado Denver Department of Physics, Denver, CO, 4University of Colorado Denver, Aurora, CO, 5University of Colorado Denver Department of Mathematical and Statistical Sciences, Denver, CO, 6Stanford University, Palo Alto, CA, 7University of Nebraska Medical Center, Omaha, NE, 8Walter Reed National Military Medical Center, Bethesda, MD, 9University of Colorado Denver, Denver, CO

    Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations of antibodies to citrullinated protein antibodies (ACPA), rheumatoid factor (RF), and…
  • Abstract Number: 1710 • ACR Convergence 2021

    Clinical Outcomes of MTX-Naïve RA Patients on Filgotinib Long-term Extension Trial Initially on FIL or MTX During Phase 3 Parent Trial

    Daniel Aletaha1, Rene Westhovens2, Tatsuya Atsumi3, YingMeei Tan4, Alena Pechonkina5, Qi Gong5, Vijay Rajendran6, Sander Strengholt7 and Gerd Burmester8, 1Medical University Vienna, Vienna, Austria, 2University Hospitals KU Leuven, Maaseik, Belgium, 3Hokkaido University, Sapporo, Japan, 4Gilead Sciences, Inc, San Diego, CA, 5Gilead Sciences, Inc., Foster City, CA, 6Galapagos NV, Mechelen, Belgium, 7Galapagos, BV, New York, NY, 8Charité University Medicine Berlin, Berlin, Germany

    Background/Purpose: The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) is approved for treatment of moderately to severely active RA in Europe and Japan. In this…
  • Abstract Number: 1717 • ACR Convergence 2021

    One Year After the Publication of the American College of Rheumatology (ACR) Guidelines for Management of Reproductive Health in Rheumatic Diseases, Has Anything Changed? An Analysis of Rheumatology Practice at a Tertiary Care Medical Center

    Yixuan Zhou1 and Sobia Hassan2, 1Rush University Medical Center, Chicago, IL, 2RUSH University, Chicago, IL

    Background/Purpose: Successful pregnancies in patients with rheumatic disease are possible when they are well-monitored, adequately treated, and planned during periods of disease quiescence. Previously, a…
  • Abstract Number: 1721 • ACR Convergence 2021

    A Womb with Rheum: Women’s Health Providers’ Confidence and Educational Needs in the Care of Those with Rheumatic Diseases

    Lauren He, Rachel Karani, Gabriel Arenas and Cuoghi Edens, University of Chicago, Chicago, IL

    Background/Purpose: Reproductive age women with rheumatic diseases are commonly cared for by non-rheumatologists who provide contraceptive counseling, preconception, pregnancy, and post-partum management. When women’s health…
  • Abstract Number: 1682 • ACR Convergence 2021

    Impact of Type, Dose and Duration of Oral Polyunsaturated Fatty Acid Supplementation on Disease Activity in Inflammatory Rheumatic Diseases: A Systematic Literature Review and Meta-analysis

    Johanna Sigaux1, Sylvain Mathieu2, Yann N guyen3, Pauline Sanchez4, Jean-Guillaume LETAROUILLY5, Martin Soubrier2, sebastien czernichow6, Rene-Marc FLIPO7, Jeremie Sellam8 and Claire Daïen4, 1Department of Rheumatology, Hôpital Avicenne, APHP, INSERM U1125, Université Sorbonne Paris Nord, Bobigny, France, 2Department of Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France, 3Department of Internal Medicine, Hôpital Beaujon, APHP nord, Université de Paris, F-92100 Clichy, France, Paris, France, 4Department of Rheumatology, CHU de Montpellier, & University of Montpellier, PhyMedExp, INSERM, CNRS UMR, Montpellier FRANCE University of Montpellier, PhyMedExp, INSERM, CNRS UMR, Montpellier, France, 5Rheumatology Department, University Hospital of Lille, Lille, France, 6Department of Nutrition, Specialized Obesity Center, Hôpital Européen Georges Pompidou, Université de Paris, Paris, France, 7Rheumatology Department, Lille University Hospital, Lille, France, 8INSERM UMRS_938, Sorbonne Université, St-Antoine Hospital, Paris, France, Paris, France

    Background/Purpose: This systematic literature review and meta-analysis aimed to better estimate the effect of oral supplementation with polyunsaturated fatty acid (PUFA; omega (n)-3 and n-6)…
  • Abstract Number: 1700 • ACR Convergence 2021

    Pharmacokinetic Boosting to Enable Once-Daily Reduced Dose Tofacitinib

    Céleste van der Togt1, Lise Verhoef2, Nathan den Broeder3, Rob ter Heine3, Bart van den Bemt4 and Alfons den Broeder5, 1Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, 2Sint Maartenskliniek, Nijmegen, Netherlands, 3Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands, 4Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, 5Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands

    Background/Purpose: Tofacitinib is an effective, yet costly, drug for treatment of RA and PsA. Tofacitinib is metabolized mainly by the cytochrome P450-enzyme CYP3A4, and the…
  • « Previous Page
  • 1
  • …
  • 543
  • 544
  • 545
  • 546
  • 547
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology